Ranbaxy Laboratories has rallied 5% to Rs 433 on NSE after the pharmaceutical company said that it has resumed production of generic Lipitor for supply to the US market.
"We are working with the US Food and Drug Administration (USFDA), and have identified and implemented multiple corrective and preventive actions," Ranbaxy said in a statement.
"As part of the first step in initiating the manufacturing process to resume supplies to the US market, we have commenced the production of the drug substance for our generic Lipitor product," the company added.
In November 2012, Ranbaxy Pharmaceutical Inc, the US subsidiary of Ranbaxy Laboratories had initiated a voluntary recall of select batches and strengths of Atorvastatin calcium tablets only in the U.S.A.
Meanwhile, the board of directors of the company will meet tomorrow (February 26, 2013) to consider and approve audited financial results for the quarter and financial year ended December 31, 2012.
The stock opened at Rs 422 and has seen a combined 723,399 shares changing hands on the counter on NSE and BSE.
"We are working with the US Food and Drug Administration (USFDA), and have identified and implemented multiple corrective and preventive actions," Ranbaxy said in a statement.
"As part of the first step in initiating the manufacturing process to resume supplies to the US market, we have commenced the production of the drug substance for our generic Lipitor product," the company added.
In November 2012, Ranbaxy Pharmaceutical Inc, the US subsidiary of Ranbaxy Laboratories had initiated a voluntary recall of select batches and strengths of Atorvastatin calcium tablets only in the U.S.A.
Meanwhile, the board of directors of the company will meet tomorrow (February 26, 2013) to consider and approve audited financial results for the quarter and financial year ended December 31, 2012.
The stock opened at Rs 422 and has seen a combined 723,399 shares changing hands on the counter on NSE and BSE.
